431 related articles for article (PubMed ID: 25648320)
1. Discovery of Akt kinase inhibitors through structure-based virtual screening and their evaluation as potential anticancer agents.
Chuang CH; Cheng TC; Leu YL; Chuang KH; Tzou SC; Chen CS
Int J Mol Sci; 2015 Feb; 16(2):3202-12. PubMed ID: 25648320
[TBL] [Abstract][Full Text] [Related]
2. Docking of protein kinase B inhibitors: implications in the structure-based optimization of a novel scaffold.
Hernández-Campos A; Velázquez-Martínez I; Castillo R; López-Vallejo F; Jia P; Yu Y; Giulianotti MA; Medina-Franco JL
Chem Biol Drug Des; 2010 Sep; 76(3):269-76. PubMed ID: 20572809
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of novel Akt1 inhibitors as anticancer agents using virtual co-crystallized pharmacophore generation.
Al-Sha'er MA; Mansi I; Almazari I; Hakooz N
J Mol Graph Model; 2015 Nov; 62():213-225. PubMed ID: 26485540
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a novel protein kinase B inhibitor by structure-based virtual screening.
Medina-Franco JL; Giulianotti MA; Yu Y; Shen L; Yao L; Singh N
Bioorg Med Chem Lett; 2009 Aug; 19(16):4634-8. PubMed ID: 19604696
[TBL] [Abstract][Full Text] [Related]
5. QSAR based docking studies of marine algal anticancer compounds as inhibitors of protein kinase B (PKBβ).
Davis GD; Vasanthi AH
Eur J Pharm Sci; 2015 Aug; 76():110-8. PubMed ID: 25936945
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, and Evaluation of a New Series of Thiazole-Based Anticancer Agents as Potent Akt Inhibitors.
Altıntop MD; Sever B; Akalın Çiftçi G; Özdemir A
Molecules; 2018 May; 23(6):. PubMed ID: 29857484
[TBL] [Abstract][Full Text] [Related]
7. Structure-based grafting and identification of kinase-inhibitors to target mTOR signaling pathway as potential therapeutics for glioblastoma.
Cui YH; Chen J; Xu T; Tian HL
Comput Biol Chem; 2015 Feb; 54():57-65. PubMed ID: 25625417
[TBL] [Abstract][Full Text] [Related]
8. New thiazole carboxamides as potent inhibitors of Akt kinases.
Chang S; Zhang Z; Zhuang X; Luo J; Cao X; Li H; Tu Z; Lu X; Ren X; Ding K
Bioorg Med Chem Lett; 2012 Jan; 22(2):1208-12. PubMed ID: 22172705
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
Li Q; Woods KW; Thomas S; Zhu GD; Packard G; Fisher J; Li T; Gong J; Dinges J; Song X; Abrams J; Luo Y; Johnson EF; Shi Y; Liu X; Klinghofer V; Des Jong R; Oltersdorf T; Stoll VS; Jakob CG; Rosenberg SH; Giranda VL
Bioorg Med Chem Lett; 2006 Apr; 16(7):2000-7. PubMed ID: 16413780
[TBL] [Abstract][Full Text] [Related]
10. Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design.
Donald A; McHardy T; Rowlands MG; Hunter LJ; Davies TG; Berdini V; Boyle RG; Aherne GW; Garrett MD; Collins I
J Med Chem; 2007 May; 50(10):2289-92. PubMed ID: 17451235
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 4-(Piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine Derivatives as Akt Inhibitors.
Liu Y; Yin Y; Zhang J; Nomie K; Zhang L; Yang D; Wang ML; Zhao G
Arch Pharm (Weinheim); 2016 May; 349(5):356-62. PubMed ID: 26991997
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 4,6-substituted-(diaphenylamino)quinazolines as potent c-Src inhibitors.
Li JR; Li DD; Fang F; Du QR; Lin L; Sun J; Qian Y; Zhu HL
Org Biomol Chem; 2013 Dec; 11(48):8375-86. PubMed ID: 24178241
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, in vitro and in silico evaluation of a new series of oxadiazole-based anticancer agents as potential Akt and FAK inhibitors.
Altıntop MD; Sever B; Akalın Çiftçi G; Turan-Zitouni G; Kaplancıklı ZA; Özdemir A
Eur J Med Chem; 2018 Jul; 155():905-924. PubMed ID: 29966916
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophore identification, virtual screening and biological evaluation of prenylated flavonoids derivatives as PKB/Akt1 inhibitors.
Dong X; Zhou X; Jing H; Chen J; Liu T; Yang B; He Q; Hu Y
Eur J Med Chem; 2011 Dec; 46(12):5949-58. PubMed ID: 22027102
[TBL] [Abstract][Full Text] [Related]
15. Discovery of pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors.
Kendall JD; O'Connor PD; Marshall AJ; Frédérick R; Marshall ES; Lill CL; Lee WJ; Kolekar S; Chao M; Malik A; Yu S; Chaussade C; Buchanan C; Rewcastle GW; Baguley BC; Flanagan JU; Jamieson SM; Denny WA; Shepherd PR
Bioorg Med Chem; 2012 Jan; 20(1):69-85. PubMed ID: 22177405
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of imidazo[1,5-a]pyridine-benzimidazole hybrids as inhibitors of both tubulin polymerization and PI3K/Akt pathway.
Kamal A; Rao AV; Nayak VL; Reddy NV; Swapna K; Ramakrishna G; Alvala M
Org Biomol Chem; 2014 Dec; 12(48):9864-80. PubMed ID: 25354805
[TBL] [Abstract][Full Text] [Related]
17. Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein kinase B (PKB β) inhibitors.
Vyas VK; Ghate M; Goel A
J Mol Graph Model; 2013 May; 42():17-25. PubMed ID: 23507201
[TBL] [Abstract][Full Text] [Related]
18. Computational approach to the identification of novel Aurora-A inhibitors.
Morshed MN; Cho YS; Seo SH; Han KC; Yang EG; Pae AN
Bioorg Med Chem; 2011 Jan; 19(2):907-16. PubMed ID: 21194953
[TBL] [Abstract][Full Text] [Related]
19. Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1.
Shan HM; Shi Y; Quan J
ChemMedChem; 2015 Jan; 10(1):158-63. PubMed ID: 25196850
[TBL] [Abstract][Full Text] [Related]
20. Discovery of spirocyclic sulfonamides as potent Akt inhibitors with exquisite selectivity against PKA.
Xu R; Banka A; Blake JF; Mitchell IS; Wallace EM; Bencsik JR; Kallan NC; Spencer KL; Gloor SL; Martinson M; Risom T; Gross SD; Morales TH; Wu WI; Vigers GP; Brandhuber BJ; Skelton NJ
Bioorg Med Chem Lett; 2011 Apr; 21(8):2335-40. PubMed ID: 21420856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
